UBS raises Estee Lauder stock price target on earnings beat By Investing.com

Estée Lauder beat fiscal Q3 EPS expectations at $0.91 versus $0.65 consensus and revenue at $3.71 billion versus $3.69 billion, while UBS raised its price target to $85 from $75 and kept a Neutral rating. The company also lifted fiscal 2026 EPS guidance and signaled fiscal 2027 top-line growth of 3% to 5% with another 150 to 200 bps of margin expansion. Shares initially jumped as much as 12% before closing up 3.4%.

Analysis

EL’s print matters less as a one-quarter beat and more as evidence that the company is finally comping through a multi-year trust deficit with both retailers and investors. The market’s fade from +12% intraday to +3% tells you the street is not paying up for a single inflection; it wants proof that margin recovery is durable and that the brand portfolio can sustain mid-single-digit growth without heavy promotional drag. In other words, the stock is transitioning from a “turnaround optionality” name to a “execution must continue” name, which usually compresses the multiple ceiling even when fundamentals improve.

The second-order winner is the prestige beauty supply chain: if EL can expand margins while reaccelerating organic sales, suppliers with leverage to premium skincare and fragrance mix should see better order visibility, while mass beauty and private-label competitors face a tougher backdrop as retailers allocate floor space to faster-growing brands. The more important implication is that the category may be stabilizing after a period of trade-down and inventory normalization; if that persists for 2-3 quarters, the knock-on benefit is improved replenishment orders across beauty distributors and select packaging firms.

The main risk is that FY27 guidance is still too early to underwrite as a de-risked compounding story. A 27x forward multiple is hard to justify unless the market believes the growth reacceleration is self-sustaining; if Asia travel retail or China demand softens, or if margins plateau after the easy recovery phase, the rerating could stall quickly. The setup is more attractive for tactical traders than long-only allocators: the near-term catalyst window is the next 1-2 quarters of confirmation, not a clean multi-year visibility story.

The contrarian view is that the market is underestimating how much of the improvement can be driven by mix and operating discipline rather than demand alone. If management is genuinely rebuilding gross margin power, EL could surprise to the upside even on only modest topline growth, because every 100 bps of margin expansion now has a larger earnings impact than it did during the downturn. That said, the current move already prices in a meaningful chunk of the rebound, so upside likely comes from continued estimate revisions rather than further multiple expansion.

Key Decisions for Investors

• Hold a tactical long EL position into the next 1-2 earnings cycles; upside is driven by estimate revisions and margin confirmation, but cap risk to a modest sizing because 27x NTM earnings leaves limited multiple expansion room.
• Use call spreads instead of outright equity for EL (3-6 month tenor) to express the “continued execution” thesis; this limits downside if the post-earnings rerate stalls while preserving upside if guidance is reaffirmed.
• Fade the move if EL rallies toward prior valuation highs without another quarter of margin upside; take profits incrementally on strength, since the stock now needs proof rather than optimism.
• Long basket idea: EL versus a consumer discretionary short basket focused on lower-quality beauty/retail names over the next 2-3 quarters; if premium beauty demand is stabilizing, the relative growth/margin gap should widen.
• Watch for a pair trade trigger on any China/travel-retail weakness: if subsequent data disappoints, rotate out of EL quickly as the stock’s new support level depends on continuity of top-line momentum.